Business condition attached to the margin of safety
uniQure has an approved product, or a regulator-agreed path to approval for AMT-130, and its operations have moved to positive owner earnings after stock compensation.
uniQure is a Dutch-domiciled gene-therapy developer. Its only revenue is royalty and license income from CSL Behring on HEMGENIX, the hemophilia B gene therapy it developed and licensed: $16.1 million in 2025, $27.1 million in 2024 and $15.8 million in 2023. Most of the royalty stream has been sold. In May 2023 uniQure received $375 million upfront from an investor (HemB SPV) in exchange for its future HEMGENIX royalties, and the filing treats this as a debt-like liability of about $473 million at the end of 2025, growing by non-cash interest of $54 million in 2025. The lead development program, AMT-130 for Huntington's disease, has no marketed product behind it yet. Owner earnings (cash from operations, less working-capital swings, stock compensation and maintenance capital spending) have been deeply negative every year we measured: about $(3.72) per share in 2023, $(4.15) in 2024 and $(3.29) in 2025, or roughly $(189) million in 2025. Cash used in operations was $178 million in 2025 against revenue of $16 million. Growth-path check: owner earnings per share improved about 21 percent in 2025, but they remain far below zero, and the improvement came from lower spending and a larger share count after the September 2025 equity offering, not from a business that earns money. Why each case is worth zero. Our method only credits value that is contracted, already operating, or the output of a long, repeated process. The company holds $624.1 million of cash, cash equivalents and investments, and says this funds operations into the second half of 2029. Under our method that cash is not added on top of an earnings stream, because the earnings stream is negative; it is being consumed by the research programs. The remaining HEMGENIX royalty income is small and largely committed to the royalty investor, so it does not offset a burn of roughly $180 million a year. Bear case: research spending continues, the regulatory path for AMT-130 stays unresolved, and no product revenue arrives. The business consumes its cash and worth nothing to shareholders on earnings we can evidence.
Base case: same, because nothing named and evidenced turns owner earnings positive.
Bull case: also zero. The obvious upside is an approved AMT-130, but on December 2025 and March 2026 the FDA told the company that its Phase I/II data compared to an external control are not sufficient evidence for approval and strongly recommended a randomized, double-blind, sham-surgery-controlled trial. There is no agreed approval path, no timetable, and no contracted sales, so we cannot credit any value for it. Other pipeline candidates (AMT-162, AMT-191, AMT-260) are early-stage and are likewise not credited. What would make this wrong: a regulator agreeing to an accelerated approval route for AMT-130, or strong HEMGENIX sales growth releasing royalties back to uniQure, would create real value that we do not count today. Because the case rests on the absence of evidenced earnings rather than a positive estimate, investors who value the pipeline directly are making a bet, not a valuation from evidenced cash flows. We did not include a value for cash on hand, which is our method's rule, and stock-based compensation of $17.7 million a year is treated as a real cost. Earlier years (2021 and 2022) are not stored because the 2021 cash flow reflects a one-time CSL license payment and we could not cleanly split working-capital items for 2022.